Randomised, Sequential, Cross-over Trial Assessing PK and PD Responses After Micro-doses of ZP4207 Administered s.c. to Patients With T1D Under eu- and Hypoglycemic Conditions and With Reference to Freshly Reconstituted Lyophilized Glucagon

Trial Profile

Randomised, Sequential, Cross-over Trial Assessing PK and PD Responses After Micro-doses of ZP4207 Administered s.c. to Patients With T1D Under eu- and Hypoglycemic Conditions and With Reference to Freshly Reconstituted Lyophilized Glucagon

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Dasiglucagon (Primary) ; Glucagon
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Zealand Pharma
  • Most Recent Events

    • 23 May 2017 Results published in a Zealand Pharma media release.
    • 20 Apr 2017 Status changed from recruiting to completed.
    • 15 Mar 2017 Results from this trial are expected in Q2 2017, according to Zealand Pharma media release,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top